New Genetic Signatures for Lung Cancer Prognostic Biomarkers Identified in Multi-Omics Study

Bottom line: A five-gene signature may improve survival predictions for lung cancer, though the findings require clinical validation. Predicting patient longevity is difficult because individual tumours possess unique genetic profiles that defy standard classification.

Lung cancer prognostic biomarkers and survival outcomes

This multi-omics study, currently a preprint awaiting peer review, analysed data from The Cancer Genome Atlas to identify genetic patterns in lung adenocarcinoma and squamous cell carcinoma. Unlike traditional single-marker tests, this method integrates mutation frequency with gene expression levels to assess risk. The researchers observed that TP53 exhibited the highest mutation frequency, which often drives aggressive tumour growth. By comparing tumour tissues against healthy samples, the team confirmed that BRCA1 and KRAS are consistently upregulated in malignant cells, suggesting their utility in distinguishing cancerous tissue from normal lung matter. The researchers measured specific alterations in TP53, ATM, BRCA1, EGFR, and KRAS. Their findings suggest that:

• Elevated levels of TP53 and BRCA1 indicate a high risk of mortality.
• Higher expression of ATM and EGFR suggests a more favourable prognosis.
• Strong functional connectivity exists between these genes in pathways controlling the cell cycle and DNA repair.

This analysis does not solve the problem of how these genetic signatures fluctuate in response to chemotherapy or immunotherapy over time. While the study utilised independent datasets for validation, it remains early-stage research. If confirmed, these lung cancer prognostic biomarkers could help clinicians organise more effective, personalised therapy regimes. However, until peer review is complete, these associations should be viewed as statistical correlations rather than confirmed clinical tools.